McKesson (NYSE: MCK), a healthcare supplier that was founded in 1833, is a value investor's dream. It has a relatively low valuation and strong long-term growth potential. Over the past three years, it also has delivered a total return of 485.64%.

The company has seen its shares rise more than 15% over the past year, though they have fallen more than 7% so far in 2023. McKesson recently raised its guidance for fiscal 2023, citing operational momentum.

The company's dividend isn't particularly generous, but its dependable revenue and net-income growth make it stand out. Considering the stock's sluggishness to start the year, does it still make sense to buy McKesson stock? Let's see.

Continue reading

Source Fool.com